Research ArticleOriginal Article

Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas

Yanwei Liu, Huiyuan Chen, Guanzhang Li, Jing Zhang, Kun Yao, Chenxing Wu, Shouwei Li and Xiaoguang Qiu
Cancer Biology & Medicine October 2022, 19 (10) 1477-1486; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0472

References

  1. 1.↵
    2. Yan H,
    3. Parsons DW,
    4. Jin G,
    5. McLendon R,
    6. Rasheed BA,
    7. Yuan W, et al.
    IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360: 765–73.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    2. Louis DN,
    3. Perry A,
    4. Wesseling P,
    5. Brat DJ,
    6. Cree IA,
    7. Figarella-Branger D, et al.
    The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23: 1231–51.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Shaw EG,
    3. Berkey B,
    4. Coons SW,
    5. Bullard D,
    6. Brachman D,
    7. Buckner JC, et al.
    Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial lowgrade glioma: results of a prospective clinical trial. J Neurosurg. 2008; 109: 835–41.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    2. Hu H,
    3. Mu Q,
    4. Bao Z,
    5. Chen Y,
    6. Liu Y,
    7. Chen J, et al.
    Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor. Cell. 2018; 175: 1665–78.
    OpenUrlCrossRefPubMed
  5. 5.
    2. Wong QH,
    3. Li KK,
    4. Wang WW,
    5. Malta TM,
    6. Noushmehr H,
    7. Grabovska Y, et al.
    Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas. Mod Pathol. 2021; 34: 1245–60.
    OpenUrl
  6. 6.↵
    2. Yu Y,
    3. Villanueva-Meyer J,
    4. Grimmer MR,
    5. Hilz S,
    6. Solomon DA,
    7. Choi S, et al.
    Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro Oncol. 2021; 23: 1872–84.
    OpenUrl
  7. 7.↵
    2. Miller JJ,
    3. Loebel F,
    4. Juratli TA,
    5. Tummala SS,
    6. Williams EA,
    7. Batchelor TT, et al.
    Accelerated progression of IDH mutant glioma after first recurrence. Neuro Oncol. 2019; 21: 669–77.
    OpenUrlCrossRef
  8. 8.↵
    2. Rohle D,
    3. Popovici-Muller J,
    4. Palaskas N,
    5. Turcan S,
    6. Grommes C,
    7. Campos C, et al.
    An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013; 340: 626–30.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    2. Dang L,
    3. Yen K,
    4. Attar EC.
    IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol. 2016; 27: 599–608.
    OpenUrlCrossRefPubMed
  10. 10.↵
    2. Platten M,
    3. Bunse L,
    4. Wick A,
    5. Bunse T,
    6. Le Cornet L,
    7. Harting I, et al.
    A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature. 2021; 592: 463–8.
    OpenUrlCrossRefPubMed
  11. 11.↵
    2. Bell EH,
    3. Zhang P,
    4. Shaw EG,
    5. Buckner JC,
    6. Barger GR,
    7. Bullard DE, et al.
    Comprehensive genomic analysis in NRG Oncology/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J Clin Oncol. 2020; 38: 3407–17.
    OpenUrl
  12. 12.↵
    2. Baumert BG,
    3. Hegi ME,
    4. van den Bent MJ,
    5. von Deimling A,
    6. Gorlia T,
    7. Hoang-Xuan K, et al.
    Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016; 17: 1521–32.
    OpenUrl
  13. 13.↵
    2. Chai RC,
    3. Chang YZ,
    4. Chang X,
    5. Pang B,
    6. An SY,
    7. Zhang KN, et al.
    YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m(6)A modification to activate NF-kappaB and promote the malignant progression of glioma. J Hematol Oncol, 2021; 14: 109.
    OpenUrlPubMed
  14. 14.↵
    2. Tom MC,
    3. Park DYJ,
    4. Yang K,
    5. Leyrer CM,
    6. Wei W,
    7. Jia X, et al.
    Malignant transformation of molecularly classified adult low-grade glioma. Int J Radiat Oncol Biol Phys. 2019; 105: 1106–12.
    OpenUrlCrossRefPubMed
  15. 15.↵
    2. Murphy ES,
    3. Leyrer CM,
    4. Parsons M,
    5. Suh JH,
    6. Chao ST,
    7. Yu JS, et al.
    Risk factors for malignant transformation of low-grade glioma. Int J Radiat Oncol Biol Phys. 2018; 100: 965–71.
    OpenUrlCrossRefPubMed
  16. 16.↵
    2. Ellingson BM,
    3. Chung C,
    4. Pope WB,
    5. Boxerman JL,
    6. Kaufmann TJ.
    Pseudoprogression, radionecrosis, inflammation or true tumor progression? Challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol. 2017; 134: 495–504.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Strauss SB,
    3. Meng A,
    4. Ebani EJ,
    5. Chiang GC.
    Imaging glioblastoma posttreatment: progression, pseudoprogression, pseudoresponse, radiation necrosis. Radiol Clin North Am. 2019; 57: 1199–216.
    OpenUrl
  18. 18.↵
    2. Qazi MA,
    3. Vora P,
    4. Venugopal C,
    5. Sidhu SS,
    6. Moffat J,
    7. Swanton C, et al.
    Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Ann Oncol. 2017; 28: 1448–56.
    OpenUrlCrossRefPubMed
  19. 19.↵
    2. Hu LS,
    3. Baxter LC,
    4. Smith KA,
    5. Feuerstein BG,
    6. Karis JP,
    7. Eschbacher JM, et al.
    Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol. 2009; 30: 552–8.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    2. van den Bent MJ,
    3. Afra D,
    4. de Witte O,
    5. Ben Hassel M,
    6. Schraub S,
    7. Hoang-Xuan K, et al.
    Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005; 366: 985–90.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    2. Gorlia T,
    3. Wu W,
    4. Wang M,
    5. Baumert BG,
    6. Mehta M,
    7. Buckner JC, et al.
    New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. Neuro Oncol. 2013; 15: 1568–79.
    OpenUrlCrossRefPubMed
  22. 22.↵
    2. Jiang T,
    3. Nam DH,
    4. Ram Z,
    5. Poon WS,
    6. Wang J,
    7. Boldbaatar D, et al.
    Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2021; 499: 60–72.
    OpenUrl
  23. 23.↵
    2. Liu Y,
    3. Liu S,
    4. Li G,
    5. Li Y,
    6. Chen L,
    7. Feng J, et al.
    Association of high-dose radiotherapy with improved survival in patients with newly diagnosed low-grade gliomas. Cancer-Am Cancer Soc. 2022; 128: 1085–92.
    OpenUrl
  24. 24.↵
    2. Liu Y,
    3. Li Y,
    4. Wang P,
    5. Chen L,
    6. Feng J,
    7. Qiu X.
    High-dose radiotherapy in newly diagnosed low-grade gliomas with nonmethylated O(6)-methylguanine-DNA methyltransferase. Radiat Oncol. 2021; 16: 157.
    OpenUrl
  25. 25.↵
    2. Wang Z,
    3. Liu L,
    4. Ji J,
    5. Zhang J,
    6. Yan M,
    7. Zhang J, et al.
    ABO blood group system and gastric cancer: a case-control study and meta-analysis. Int J Mol Sci. 2012; 13: 13308–21.
    OpenUrlPubMed
  26. 26.↵
    2. Liumbruno GM,
    3. Franchini M.
    Beyond immunohaematology: the role of the ABO blood group in human diseases. Blood Transfus. 2013; 11: 491–9.
    OpenUrlPubMed
  27. 27.↵
    2. Zhang Z,
    3. Chan AK,
    4. Ding X,
    5. Li Y,
    6. Zhang R,
    7. Chen L, et al.
    Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas. Neuro Oncol. 2017; 19: 1008–10.
    OpenUrl
  28. 28.↵
    2. Zepeda-Mendoza CJ,
    3. Vaubel RA,
    4. Zarei S,
    5. Ida CM,
    6. Matthews M,
    7. Acree S, et al.
    Concomitant 1p/19q co-deletion and IDH1/2, ATRX, and TP53 mutations within a single clone of “dual-genotype” IDH-mutant infiltrating gliomas. Acta Neuropathol. 2020; 139: 1105–07.
    OpenUrl
  29. 29.↵
    2. Venteicher AS,
    3. Tirosh I,
    4. Hebert C,
    5. Yizhak K,
    6. Neftel C,
    7. Filbin MG, et al.
    Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science. 2017; 355: eaai8478.
  30. 30.↵
    2. Wang Y,
    3. Li S,
    4. Chen L,
    5. You G,
    6. Bao Z,
    7. Yan W, et al.
    Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro Oncol. 2012; 14: 518–25.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords